x
Ariana Pharma
[contact-form-7 404 "Not Found"]

Ariana Pharma
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News & more
    • In The News
    • Case study
    • Publications
      • Publications & Conferences
      • Whitepaper & blog
  • Careers
Logo

Contact Info

  • 58-60 Avenue de la Grande Armée, 75017, Paris, France
  • +33 1 44 37 17 00
  • info@arianapharma.com

Identification of Comorbidities in Influenza: A Comprehensive Retrospective Cohort Study

Overview

KEM® has been applied to analyze data from a large retrospective cohort study on hospital admissions due to influenza in Brazil and Mexico. 126 million of hospital records from Mexico SAEH and Brazil SIHSUS databases were included in the analysis. This study identifies key demographic factors and comorbidities influencing the risk and severity of influenza, aiming to enhance healthcare responses during influenza seasons.

Impact

• KEM® xAI technology enabled the identification of strong relations between age, comorbidities, and the severity of influenza outcomes. Specifically, the presence of cardiovascular diseases has been linked to increased mortality among influenza patients.

• This research supports the development of specific diagnostic and treatment protocols that could improve patient management and outcomes, particularly in populations at higher risk due to age and existing health conditions.

Objectives

• Map the impact of patient characteristics on the severity of influenza, providing actionable insights to healthcare providers and policymakers. 

• Contribute to the development and improvement of data analysis methods to study large-scale health databases, enhancing the reliability of the findings across different regions and seasons.

 

Method

Employing KEM® xAI, the study systematically processed and analyzed 23 million records from the Mexico SAEH database and 103 million records from the Brazil SIHSUS database. The analysis focused on seasonality, regional differences, and the relationships between patient characteristics and hospital admission rates for influenza.

Results

• The study successfully highlighted age and specific comorbidities, such as cardiovascular diseases, as critical predictors of severe influenza outcomes.

• The research also underscored the variability of influenza impact based on seasonal and regional factors, enhancing the understanding of how influenza affects different populations.

Ariana Pharmaceuticals, The AI DRUG Development Company

  • Paris, FRANCE / Cambridge, MA, USA
  • Call Us: +33 144 37 17 00
  • info@arianapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Ariana Pharma © 2024 All Rights Reserved